Pregabalin; Lorazepam; Pregabalin; Placebo
Long Term Safety And Efficacy Study Of Pregabalin (Lyrica) In Subjects With Generalized Anxiety Disorder
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00624780/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза IV — препарат уже зарегистрирован. Собирают дополнительные сведения о пользе и безопасности при обычном применении.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–65 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 615 чел. во всех странах исследования.
- Плановая дата окончания (04.2012) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 3 · невключение: 3
Критерии включения
- Diagnosis Generalized Anxiety Disorder
- HAM-A score >=18 and HAM-D (item 1) score >=2 at screening and baseline
- Needs pharmacological treatment
Критерии невключения
- Current or past diagnosis of any other DSM IV Axis I disorders
- A history of failed treatment with a benzodiazepine
- Any clinically significant, serious, or unstable hematologic, autoimmune, endocrine, cardiovascular, renal, hepatic, gastrointestinal, or neurological disorder
Источник: ClinicalTrials.gov, NCT00624780 · запись обновлена в реестре 28 января 2021.
Дизайн и результаты
Что измеряют — первичные конечные точки (10), вторичных — 28
- Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1 — Baseline, Week 1 post-treatment discontinuation (discontinuation occurred prior to Week 9)
- Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 2 — Baseline, Week 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
- Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1 — Baseline, Week 1 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
- Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 2 — Baseline, Week 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
- Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1 — Baseline, Week 1 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
- Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 2 — Baseline, Week 2 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
- Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1 — Last visit on treatment, Week 1 post-treatment discontinuation (discontinuation occurred prior to Week 9)
- Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 2 — Last visit on treatment, Week 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
- Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1 — Last visit on treatment, Week 1 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
- Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 2 — Last visit on treatment, Week 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
Цель исследования
The purpose of this study is to characterize the safety and efficacy in patients with generalized anxiety disorder after short- (3 months) and long-term (6 months) use of Pregabalin (Lyrica).
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00624780 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.